Poly (ADP-ribose) polymerase inhibition: past, present and future
The process of poly (ADP-ribosyl) ation and the major enzyme that catalyses this reaction,
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …
PARP and PARG inhibitors in cancer treatment
D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …
genomic instability through radiotherapy and chemotherapy has been a powerful but …
PARP14 is a PARP with both ADP-ribosyl transferase and hydrolase activities
N Đukić, Ø Strømland, JD Elsborg, D Munnur, K Zhu… - Science …, 2023 - science.org
PARP14 is a mono–ADP-ribosyl transferase involved in the control of immunity,
transcription, and DNA replication stress management. However, little is known about the …
transcription, and DNA replication stress management. However, little is known about the …
A proteome-wide atlas of drug mechanism of action
Defining the cellular response to pharmacological agents is critical for understanding the
mechanism of action of small molecule perturbagens. Here, we developed a 96-well-plate …
mechanism of action of small molecule perturbagens. Here, we developed a 96-well-plate …
ADP-ribosylation from molecular mechanisms to therapeutic implications
ADP-ribosylation is a ubiquitous modification of biomolecules, including proteins and
nucleic acids, that regulates various cellular functions in all kingdoms of life. The recent …
nucleic acids, that regulates various cellular functions in all kingdoms of life. The recent …
A decade of FDA-approved drugs (2010–2019): trends and future directions
A total of 378 novel drugs and 27 biosimilars approved by the US Food and Drug
Administration (FDA) between 2010 and 2019 were evaluated according to approval …
Administration (FDA) between 2010 and 2019 were evaluated according to approval …
Establishment of porcine and human expanded potential stem cells
X Gao, M Nowak-Imialek, X Chen, D Chen… - Nature cell …, 2019 - nature.com
We recently derived mouse expanded potential stem cells (EPSCs) from individual
blastomeres by inhibiting the critical molecular pathways that predispose their differentiation …
blastomeres by inhibiting the critical molecular pathways that predispose their differentiation …
Inhibitors of PARP: Number crunching and structure gazing
Selective inhibitors of PARP1 and PARP2 (PARP1/2) are used to treat cancer patients with
deficiencies in the repair of DNA via homologous recombination. Here we provide a …
deficiencies in the repair of DNA via homologous recombination. Here we provide a …
PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
The discovery of poly (ADP-ribose)> 50 years ago opened a new field, leading the way for
the discovery of the poly (ADP-ribose) polymerase (PARP) family of enzymes and the ADP …
the discovery of the poly (ADP-ribose) polymerase (PARP) family of enzymes and the ADP …
[HTML][HTML] Targeted therapy for breast cancer: An overview of drug classes and outcomes
AT Jacobs, DM Castaneda-Cruz, MM Rose… - Biochemical …, 2022 - Elsevier
The last 25 years have seen significant growth in new therapeutic options for breast cancer,
termed targeted therapies based on their ability to block specific pathways known to drive …
termed targeted therapies based on their ability to block specific pathways known to drive …